A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
Public ClinicalTrials.gov record NCT05176639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Safety, Tolerability, and Efficacy Study of Veligrotug, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor in Subjects With Thyroid Eye Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with thyroid eye disease (TED). The primary objective of this clinical trial is to establish the safety, tolerability, and efficacy of veligrotug, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of veligrotug in active TED participants who received 10 milligrams (mg)/kilogram (kg).
Study identification
- NCT ID
- NCT05176639
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 113 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2022
- Primary completion
- Jul 14, 2024
- Completion
- Mar 26, 2025
- Last update posted
- Aug 12, 2026
2022 – 2025
United States locations
- U.S. sites
- 29
- U.S. states
- 14
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado - Department of Ophthalmology | Aurora | California | 80045 | — |
| The Private Office of Raymond Douglas | Beverly Hills | California | 90210 | — |
| USC Roski Eye Institute | Los Angeles | California | 90033 | — |
| MACRO Trials, Inc. | Los Angeles | California | 90049 | — |
| Amy Patel Jain, MD | Newport Beach | California | 92260 | — |
| Byers Eye Institute/Stanford University | Palo Alto | California | 94303 | — |
| Senta Clinic | San Diego | California | 95207 | — |
| University of California, San Francisco | San Francisco | California | 94158 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Sina Medical Center | Homestead | Florida | 33034 | — |
| Med-Care Research Inc. | Miami | Florida | 33125 | — |
| Edward Jenner Research Group Center LLC | Plantation | Florida | 33317 | — |
| Sarasota Retina Institute | Sarasota | Florida | 34231 | — |
| Vision Medical Research Inc. | Orland Park | Illinois | 60462 | — |
| University Health Diabetes, Endocrinology & Nephrology Center | Kansas City | Kansas | 64108 | — |
| KU Medical Center, University of Kansas | Kansas City | Kansas | 66103 | — |
| Massachusetts Eye and Ear | Boston | Massachusetts | 02114 | — |
| Ophthalmic Consultants of Boston | Weymouth | Massachusetts | 02189 | — |
| Fraser Eye Care Center | Fraser | Michigan | 48026 | — |
| Kahana Oculoplastic & Orbital Surgery | Livonia | Michigan | 48152 | — |
| University of Minnesota, Department of Ophthalmology and Visual Neurosciences | Minneapolis | Minnesota | 55455 | — |
| Advanced Research International, LLC | Las Vegas | Nevada | 89144 | — |
| Rutgers-New Jersey Medical School-Newark | Newark | New Jersey | 07103 | — |
| New York Eye Ear Infirmary of Mount Sinai | New York | New York | 10003 | — |
| Baylor College of Medicine (BCM)-Ophthalmology | Houston | Texas | 77030 | — |
| Neuro-Eye Clinical Trials | Houston | Texas | 77074 | — |
| Neuro-Ophthalmology of Texas PLLC | Houston | Texas | 77074 | — |
| University of Vermont Medical Center | Burlington | Vermont | 05401 | — |
| West Virgina University Eye Institute | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05176639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 12, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05176639 live on ClinicalTrials.gov.